Arcellx, CAR T Therapy, CART DDBCMA, chimeric antigen receptor, Kite Pharma, multiple myeloma
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic..
BALL, Brexucabtagene autoleucel, Kite Pharma, Tecartus, ZUMA-3
Brexucabtagene autoleucel is approved by FDA for relapsed or refractory B-cell precursor acute lymphoblastic leukemia
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). In Z..
axicabtagene ciloleucel, CAR - T Cell therapy, CD19, follicular lymphoma, Kite Pharma, refractory follicular lymphoma, relapsed follicular lymphoma, Yescarta
The FDA has granted axicabtagene ciloleucel expedited approval for relapsed or refractory follicular lymphoma.
August 2021: The FDA has given axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) expedited approval for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.A single-a..